In agreement, beta1-syntrophin, a component of the dystrophin-glycoprotein complex (DAPC) that is altered in DMD and BMD, was shown to be a target of miR-222, and its expression was found downregulated in mouse dystrophic muscles where miR-222 levels are increased [35]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.